Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia

Asha Pillai, Christine Hartford, Chong Wang, Deqing Pei, Jie Yang, Ashok Srinivasan, Brandon Triplett, Mari Dallas, Wing Leung

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from MSD vs. MUD donors. Conditioning was CTX 200 mg/kg (CTX) + rabbit ATG 10 mg/kg (ATG) for MSD (n = 9) and TLI (800 cGy) + CTX/ATG for MUD HCT (n = 5). Immunoprophylaxis was CSA and short-course MTX. Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr. Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for MSD and MUD cohorts. EFS and stable engraftment rate were 100%. CIN of acute GVHD was: MSD, Grade I-II: 1 (11%), Grade III-IV: 0%; MUD, Grade I-II: 1 (20%), Grade III-IV: 1 (20%). CIN of chronic GVHD was: MSD, limited: 1 (11%), extensive: 0%; MUD, limited: 0%, extensive: 0%. All immunosuppressive-compliant patients successfully weaned immunosuppression. Although in limited patients, our results suggest that immunomodulatory TLI added to backbone CTX/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial.

Original languageEnglish (US)
Pages (from-to)628-634
Number of pages7
JournalPediatric Transplantation
Volume15
Issue number6
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Unrelated Donors
Aplastic Anemia
Hematopoietic Stem Cell Transplantation
Pediatrics
Immunosuppressive Agents
Immunosuppression
Bone Marrow
Outcome Assessment (Health Care)
Tissue Donors
Clinical Trials
Rabbits
Transplants
Incidence

Keywords

  • aplastic anemia engraftment
  • graft-versus-host disease
  • hematopoietic stem cell transplantation
  • non-myeloablative
  • pediatrics
  • transplant tolerance

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. / Pillai, Asha; Hartford, Christine; Wang, Chong; Pei, Deqing; Yang, Jie; Srinivasan, Ashok; Triplett, Brandon; Dallas, Mari; Leung, Wing.

In: Pediatric Transplantation, Vol. 15, No. 6, 01.09.2011, p. 628-634.

Research output: Contribution to journalArticle

Pillai, Asha ; Hartford, Christine ; Wang, Chong ; Pei, Deqing ; Yang, Jie ; Srinivasan, Ashok ; Triplett, Brandon ; Dallas, Mari ; Leung, Wing. / Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. In: Pediatric Transplantation. 2011 ; Vol. 15, No. 6. pp. 628-634.
@article{ebd12ff4157f42208a365452c2441a4b,
title = "Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia",
abstract = "To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from MSD vs. MUD donors. Conditioning was CTX 200 mg/kg (CTX) + rabbit ATG 10 mg/kg (ATG) for MSD (n = 9) and TLI (800 cGy) + CTX/ATG for MUD HCT (n = 5). Immunoprophylaxis was CSA and short-course MTX. Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr. Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for MSD and MUD cohorts. EFS and stable engraftment rate were 100{\%}. CIN of acute GVHD was: MSD, Grade I-II: 1 (11{\%}), Grade III-IV: 0{\%}; MUD, Grade I-II: 1 (20{\%}), Grade III-IV: 1 (20{\%}). CIN of chronic GVHD was: MSD, limited: 1 (11{\%}), extensive: 0{\%}; MUD, limited: 0{\%}, extensive: 0{\%}. All immunosuppressive-compliant patients successfully weaned immunosuppression. Although in limited patients, our results suggest that immunomodulatory TLI added to backbone CTX/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial.",
keywords = "aplastic anemia engraftment, graft-versus-host disease, hematopoietic stem cell transplantation, non-myeloablative, pediatrics, transplant tolerance",
author = "Asha Pillai and Christine Hartford and Chong Wang and Deqing Pei and Jie Yang and Ashok Srinivasan and Brandon Triplett and Mari Dallas and Wing Leung",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1399-3046.2011.01542.x",
language = "English (US)",
volume = "15",
pages = "628--634",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia

AU - Pillai, Asha

AU - Hartford, Christine

AU - Wang, Chong

AU - Pei, Deqing

AU - Yang, Jie

AU - Srinivasan, Ashok

AU - Triplett, Brandon

AU - Dallas, Mari

AU - Leung, Wing

PY - 2011/9/1

Y1 - 2011/9/1

N2 - To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from MSD vs. MUD donors. Conditioning was CTX 200 mg/kg (CTX) + rabbit ATG 10 mg/kg (ATG) for MSD (n = 9) and TLI (800 cGy) + CTX/ATG for MUD HCT (n = 5). Immunoprophylaxis was CSA and short-course MTX. Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr. Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for MSD and MUD cohorts. EFS and stable engraftment rate were 100%. CIN of acute GVHD was: MSD, Grade I-II: 1 (11%), Grade III-IV: 0%; MUD, Grade I-II: 1 (20%), Grade III-IV: 1 (20%). CIN of chronic GVHD was: MSD, limited: 1 (11%), extensive: 0%; MUD, limited: 0%, extensive: 0%. All immunosuppressive-compliant patients successfully weaned immunosuppression. Although in limited patients, our results suggest that immunomodulatory TLI added to backbone CTX/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial.

AB - To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from MSD vs. MUD donors. Conditioning was CTX 200 mg/kg (CTX) + rabbit ATG 10 mg/kg (ATG) for MSD (n = 9) and TLI (800 cGy) + CTX/ATG for MUD HCT (n = 5). Immunoprophylaxis was CSA and short-course MTX. Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr. Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for MSD and MUD cohorts. EFS and stable engraftment rate were 100%. CIN of acute GVHD was: MSD, Grade I-II: 1 (11%), Grade III-IV: 0%; MUD, Grade I-II: 1 (20%), Grade III-IV: 1 (20%). CIN of chronic GVHD was: MSD, limited: 1 (11%), extensive: 0%; MUD, limited: 0%, extensive: 0%. All immunosuppressive-compliant patients successfully weaned immunosuppression. Although in limited patients, our results suggest that immunomodulatory TLI added to backbone CTX/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial.

KW - aplastic anemia engraftment

KW - graft-versus-host disease

KW - hematopoietic stem cell transplantation

KW - non-myeloablative

KW - pediatrics

KW - transplant tolerance

UR - http://www.scopus.com/inward/record.url?scp=80052097795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052097795&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2011.01542.x

DO - 10.1111/j.1399-3046.2011.01542.x

M3 - Article

VL - 15

SP - 628

EP - 634

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

ER -